Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 642046, 8 pages
http://dx.doi.org/10.1155/2015/642046
Research Article

The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients

1Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China
2Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China
3Department of Thyroid and Breast Surgery, West China Hospital, Sichuan University, Chengdu 610041, China

Received 20 May 2015; Revised 13 July 2015; Accepted 14 July 2015

Academic Editor: Diego Russo

Copyright © 2015 Li-Bo Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. La Vecchia, M. Malvezzi, C. Bosetti et al., “Thyroid cancer mortality and incidence: a global overview,” International Journal of Cancer, vol. 136, no. 9, pp. 2187–2195, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. Y.-Q. Liu, S.-Q. Zhang, W.-Q. Chen et al., “Trend of incidence and mortality on thyroid cancer in China during 2003–2007,” Zhonghua Liu Xing Bing Xue Za Zhi, vol. 33, no. 10, pp. 1044–1048, 2012. View at Google Scholar · View at Scopus
  3. L. Davies and H. G. Welch, “Increasing incidence of thyroid cancer in the United States, 1973–2002,” The Journal of the American Medical Association, vol. 295, no. 18, pp. 2164–2167, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Leenhardt, P. Grosclaude, and L. Chérié-Challine, “Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the french thyroid cancer committee,” Thyroid, vol. 14, no. 12, pp. 1056–1060, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. S. A. Hundahl, I. D. Fleming, A. M. Fremgen, and H. R. Menck, “A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995,” Cancer, vol. 83, no. 12, pp. 2638–2648, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. E. Nikiforov, “Molecular analysis of thyroid tumors,” Modern Pathology, vol. 24, supplement 2, pp. S34–S43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Xing, “BRAF mutation in thyroid cancer,” Endocrine-Related Cancer, vol. 12, no. 2, pp. 245–262, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Jeong, Y. Jeong, J. H. Park et al., “BRAF V600E mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR,” Annals of Surgical Oncology, vol. 20, no. 3, pp. 759–766, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Zheng, T. Xia, L. Lin et al., “BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China,” World Journal of Surgical Oncology, vol. 10, article 104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. K.-L. Lin, O.-C. Wang, X.-H. Zhang, X.-X. Dai, X.-Q. Hu, and J.-M. Qu, “The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma,” Annals of Surgical Oncology, vol. 17, no. 12, pp. 3294–3300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. Y.-S. Kim, J.-S. Kim, J.-S. Bae, and W.-C. Park, “Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma,” World Journal of Surgical Oncology, vol. 11, article 99, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Yasuhiro, H. Yoshida, R. Maruo et al., “BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients,” Endocrine Journal, vol. 56, no. 1, pp. 89–97, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Bozec, O. Dassonville, E. Chamorey et al., “Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases,” European Archives of Oto-Rhino-Laryngology, vol. 268, no. 8, pp. 1205–1212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. D. Podnos, D. Smith, L. D. Wagman, and J. D. I. Ellenhorn, “The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer,” American Surgeon, vol. 71, no. 9, pp. 731–734, 2005. View at Google Scholar · View at Scopus
  15. S. Scherl, S. Mehra, J. Clain et al., “The effect of surgeon experience on the detection of metastatic lymph nodes in the central compartment and the pathologic features of clinically unapparent metastatic lymph nodes: what are we missing when we don't perform a prophylactic dissection of central compartment lymph nodes in papillary thyroid cancer?” Thyroid, vol. 24, no. 8, pp. 1282–1288, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Shimamoto, H. Satake, A. Sawaki, T. Ishigaki, H. Funahashi, and T. Imai, “Preoperative staging of thyroid papillary carcinoma with ultrasonography,” European Journal of Radiology, vol. 29, no. 1, pp. 4–10, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Li, P. Aragon Han, K. C. Lee et al., “Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? results from four endocrine surgery centers,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 9, pp. 3702–3712, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. G. M. Howell, M. N. Nikiforova, S. E. Carty et al., “BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer,” Annals of Surgical Oncology, vol. 20, no. 1, pp. 47–52, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. K. C. Lee, C. Li, E. B. Schneider et al., “Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?” Surgery, vol. 152, no. 6, pp. 977–983, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J.-Y. Joo, J.-Y. Park, Y.-H. Yoon et al., “Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 11, pp. 3996–4003, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Riesco-Eizaguirre, I. Rodríguez, A. De la Vieja et al., “The BRAFV600E oncogene induces transforming growth factor β secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer,” Cancer Research, vol. 69, no. 21, pp. 8317–8325, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Oler and J. M. Cerutti, “High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes,” Cancer, vol. 115, no. 5, pp. 972–980, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Durante, E. Puxeddu, E. Ferretti et al., “Brief report: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 7, pp. 2840–2843, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Russo, G. Damante, E. Puxeddu, C. Durante, and S. Filetti, “Epigenetics of thyroid cancer and novel therapeutic targets,” Journal of Molecular Endocrinology, vol. 46, no. 3, pp. R73–R81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. D. A. Kleiman, D. Buitrago, M. J. Crowley et al., “Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing,” Journal of Surgical Research, vol. 182, no. 1, pp. 85–93, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. D. N. Hayes, A. S. Lucas, T. Tanvetyanon et al., “Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements,” Clinical Cancer Research, vol. 18, no. 7, pp. 2056–2065, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Nucera, M. A. Nehs, S. S. Nagarkatti et al., “Targeting BRAFV600E with PLX4720 displays potent antimigratory and Anti-invasive activity in preclinical models of human thyroid cancer,” Oncologist, vol. 16, no. 3, pp. 296–309, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Hersey, L. Bastholt, V. Chiarion-Sileni et al., “Small molecules and targeted therapies in distant metastatic disease,” Annals of Oncology, vol. 20, no. 4, pp. vi35–vi40, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. M. Wilhelm, C. Carter, L. Tang et al., “BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis,” Cancer Research, vol. 64, no. 19, pp. 7099–7109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Grande, J. J. Díez, C. Zafon, and J. Capdevila, “Thyroid cancer: molecular aspects and new therapeutic strategies,” Journal of Thyroid Research, vol. 2012, Article ID 847108, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. E. Nikiforov, “Thyroid carcinoma: molecular pathways and therapeutic targets,” Modern Pathology, vol. 21, supplement 2, pp. S37–S43, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Truong, Y. Rougier, D. Dubourdieu et al., “Time trends and geographic variations for thyroid cancer in New Caledonia, a very high incidence area (1985–1999),” European Journal of Cancer Prevention, vol. 16, no. 1, pp. 62–70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Albores-Saavedra, D. E. Henson, E. Glazer, and A. M. Schwartz, “Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype—papillary, follicular, and anaplastic: a morphological and epidemiological study,” Endocrine Pathology, vol. 18, no. 1, pp. 1–7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Lubina, O. Cohen, M. Barchana et al., “Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase,” Thyroid, vol. 16, no. 10, pp. 1033–1040, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Stanojevic, R. Dzodic, V. Saenko et al., “Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia,” Endocrine Journal, vol. 58, no. 5, pp. 381–393, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. H.-Q. Guo, H. Zhao, Z.-H. Zhang, Y.-L. Zhu, T. Xiao, and Q.-J. Pan, “Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from Mainland China,” Disease Markers, vol. 2014, Article ID 912182, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. M. N. Nikiforova, E. T. Kimura, M. Gandhi et al., “BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 11, pp. 5399–5404, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Namba, M. Nakashima, T. Hayashi et al., “Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 9, pp. 4393–4397, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Kurtulmus, M. Duren, U. Ince et al., “BRAFV600E mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness,” Endocrine, vol. 42, no. 2, pp. 404–410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. S. B. B. D. Edge, C. C. Compton, A. G. Fritz, F. L. Greene, and A. Trotti, AJCC Cancer Staging Manual, Springer, New York, NY, USA, 7th edition, 2010.
  41. T. Qiu, H. Lu, L. Guo et al., “Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay,” Scientific Reports, vol. 5, article 9211, 2015. View at Publisher · View at Google Scholar
  42. R. Kansal, L. Quintanilla-Martinez, V. Datta, J. Lopategui, G. Garshfield, and B. N. Nathwani, “Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis,” Genes Chromosomes and Cancer, vol. 52, no. 1, pp. 99–106, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Mao, J. Zhou, Z. Yang et al., “KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer,” PLoS ONE, vol. 7, no. 5, Article ID e36653, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. C. M. Lovly, K. B. Dahlman, L. E. Fohn et al., “Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials,” PLoS ONE, vol. 7, no. 4, Article ID e35309, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Y. Lim, S. W. Hong, Y. S. Lee et al., “Clinicopathologic implications of the BRAFV600E mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center,” Thyroid, vol. 23, no. 11, pp. 1423–1430, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. S.-J. Kim, K. E. Lee, J. P. Myong et al., “BRAFV600E mutation is associated with tumor aggressiveness in papillary thyroid cancer,” World Journal of Surgery, vol. 36, no. 2, pp. 310–317, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Xing, D. Clark, H. Guan et al., “BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer,” Journal of Clinical Oncology, vol. 27, no. 18, pp. 2977–2982, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Nakayama, A. Yoshida, Y. Nakamura et al., “Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas,” Anticancer Research, vol. 27, no. 5, pp. 3645–3649, 2007. View at Google Scholar · View at Scopus
  49. L. Fugazzola, E. Puxeddu, N. Avenia et al., “Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 455–464, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Turanli, “Is the type of dissection in lateral neck metastasis for differentiated thyroid carcinoma important?” Otolaryngology—Head and Neck Surgery, vol. 136, no. 6, pp. 957–960, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Durante, N. Haddy, E. Baudin et al., “Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 2892–2899, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. E. L. Mazzaferri and S. M. Jhiang, “Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer,” The American Journal of Medicine, vol. 97, no. 5, pp. 418–428, 1994. View at Publisher · View at Google Scholar · View at Scopus
  53. O. Mete, L. Rotstein, and S. L. Asa, “Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension,” Annals of Surgical Oncology, vol. 17, no. 2, pp. 386–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. V. Vasko, A. V. Espinosa, W. Scouten et al., “Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 8, pp. 2803–2808, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. J. A. Knauf, M. A. Sartor, M. Medvedovic et al., “Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFΒ signaling,” Oncogene, vol. 30, no. 28, pp. 3153–3162, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Hu, D. Liu, R. P. Tufano et al., “Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer,” International Journal of Cancer, vol. 119, no. 10, pp. 2322–2329, 2006. View at Publisher · View at Google Scholar · View at Scopus